Lymphodepletion: systemic chemotherapy with acute toxicities and detrimental long-term consequences for anti-tumor immune function Dan Lymphodepletion: systemic chemotherapy with acute toxicities and detrimental long-term consequences for anti-tumor immune function Read More »
Umoja’s RACR technology drives Synthetic Receptor Enabled Differentiation (ShRED) of iPSCs, a proprietary and uniquely scalable process for manufacturing potent and persistent engineered immune effector cells Dan Umoja’s RACR technology drives Synthetic Receptor Enabled Differentiation (ShRED) of iPSCs, a proprietary and uniquely scalable process for manufacturing potent and persistent engineered immune effector cells Read More »
VivoVec: Our proprietary technology platform for in vivo gene delivery to T cells. John Policano VivoVec: Our proprietary technology platform for in vivo gene delivery to T cells. Read More »
The Next Step Forward in CAR T Development John Policano The Next Step Forward in CAR T Development Read More »